H. Dele Davies
A5037776991- SARS-CoV-2 and COVID-19 Research
- Malaria Research and Control
- COVID-19 Clinical Research Studies
- Animal Virus Infections Studies
- Mosquito-borne diseases and control
- vaccines and immunoinformatics approaches
- Complement system in diseases
- Syphilis Diagnosis and Treatment
- Respiratory viral infections research
- Computational Drug Discovery Methods
- Viral Infections and Vectors
- Biomedical Text Mining and Ontologies
- Pneumonia and Respiratory Infections
- Female Genital Mutilation/Cutting Issues
- Sex work and related issues
- Immunotherapy and Immune Responses
- Bacterial Infections and Vaccines
- Virus-based gene therapy research
- Immunodeficiency and Autoimmune Disorders
- HIV Research and Treatment
- Viral gastroenteritis research and epidemiology
- Signaling Pathways in Disease
- Viral Infections and Immunology Research
- Hepatitis B Virus Studies
- Fungal Infections and Studies
University of Oxford
2020-2024
Jenner Institute
2020-2024
Swansea University
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2021
NIHR Clinical Research Network
2021
AstraZeneca (Brazil)
2021
Oxford BioMedica (United Kingdom)
2020
University of Lisbon
2020
University of Nebraska Medical Center
2016-2018
Children's Hospital & Medical Center
2018
SummaryBackgroundCOVID-19 vaccine supply shortages are causing concerns about compromised immunity in some countries as the interval between first and second dose becomes longer. Conversely, with no constraints considering administering a third dose. We assessed persistence of immunogenicity after single ChAdOx1 nCoV-19 (AZD1222), an extended (44–45 weeks) dose, response to booster given 28–38 weeks dose.MethodsIn this substudy, volunteers aged 18–55 years who were enrolled phase 1/2...
Vaccine development against the SARS-CoV-2 virus focuses on principal target of neutralizing immune response, spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for delivery viral antigen, but it is important generation antibodies that they produce appropriately processed and assembled antigen mimics observed virus. Here, we describe structure, conformation, glycosylation S protein derived from adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We demonstrate...
Respiratory syncytial virus, the most common cause of bronchiolitis, is leading infant hospitalization in developed countries and accounts for substantial mortality morbidity developing countries. Children at increased risk severe bronchiolitis are those <6 weeks age, born prematurely with an underlying cardiopulmonary disorder or immunodeficiency. Approximately 80% cases occur first year life. By two years virtually all children have been infected by least one strain virus. Classically,...
Reducing the mortality and morbidity associated with COVID-19 remains a global health priority. Vaccines have proven highly effective at preventing infection hospitalization, but efforts must continue to improve treatment options for those who still become seriously ill.
Abstract Understanding mechanisms of antibody synergy is important for vaccine design and cocktail development. Examples between antibodies are well-documented, but the underlying these relationships often remain poorly understood. The leading blood-stage malaria candidate, CyRPA, essential invasion Plasmodium falciparum into human erythrocytes. Here we present a panel anti-CyRPA monoclonal that strongly inhibit parasite growth in vitro assays. Structural studies show growth-inhibitory bind...
The highly conserved and essential Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) has emerged as the leading target for vaccines against disease-causing blood stage of malaria. However, features human vaccine-induced antibody response that confer potent inhibition malaria parasite invasion into red cells are not well defined. Here, we characterize 236 IgG monoclonal antibodies, derived from 15 donors, induced by most advanced PfRH5 vaccine. We define antigenic landscape...
Abstract Reticulocyte-binding protein homologue 5 (RH5), a leading blood-stage Plasmodium falciparum malaria vaccine target, interacts with cysteine-rich protective antigen (CyRPA) and RH5-interacting (RIPR) to form an essential heterotrimeric “RCR-complex”. We investigate whether RCR-complex vaccination can improve upon RH5 alone. Using monoclonal antibodies (mAbs) we show that parasite growth-inhibitory epitopes on each are surface-exposed the mAb pairs targeting different antigens...
Highlights•Inhibitory antibodies from RH5.1/AS01B vaccinees target the RH5 α-helical core•A truncated and thermostabilized RH5.2 immunogen induces more potent antibodies•Bioconjugation of to VLPs enhances antibody immunogenicity in rodents•RH5.2-VLP/Matrix-M highest functional antimalarial ratsSummaryPlasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) is a leading blood-stage malaria vaccine antigen target, currently phase 2b clinical trial as full-length soluble...
Abstract The development of a highly effective vaccine against the pathogenic blood-stage infection human malaria will require delivery platform that can induce an antibody response both maximal quantity and functional quality. One strategy to achieve this includes presenting antigens immune system on virus-like particles (VLPs). Here we sought improve design Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) antigen, which is currently in Phase 2 clinical trial as...
Abstract Objective To enable reproducible research at scale by creating a platform that enables health data users to find, access, curate, and re-use electronic record phenotyping algorithms. Materials Methods We undertook structured approach identifying requirements for phenotype algorithm engaging with key stakeholders. User experience analysis was used inform the design, which we implemented as web application featuring novel metadata standard defining algorithms, access via Application...
In North America lower respiratory tract infections, consisting mainly of pneumonia and bronchiolitis, are most common in the first year life with an annual incidence 240 episodes per 1000 infants compared 134 children from ages 1 to 15 years.1 Worldwide 200 less than age is hospitalized for infections annually, a mortality rate 5%.2 addition consequences acute infection, there evidence that early infancy may be linked sequelae form chronic pulmonary disease, recurrent wheezing, fibrosis...
Abstract Vaccine development against the SARS-CoV-2 virus focuses on principal target of neutralizing immune response, spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for delivery viral antigen, but it is important generation antibodies that they produce appropriately processed and assembled antigen mimics observed virus. Here, we describe structure, conformation glycosylation S protein derived from adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We...
SUMMARY The highly conserved and essential Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) has emerged as the leading target for vaccines that seek to protect against disease-causing blood-stage of malaria. However, features human vaccine-induced antibody response confer potent inhibition malaria parasite invasion into red blood cells are not well defined. Here we characterize over 200 IgG monoclonal antibodies induced by most advanced PfRH5 vaccine. We define antigenic...
Abstract Introduction Residents of care homes for older people experience multi-factorial problems when being given oral medication. A systematic integrated mixed-methods review the literature revealed that practices modifying tablets, crushing and mixing with food, in attempts to administer medication, remain widespread internationally. There is a high prevalence swallowing problems. Care home routines are time pressured, there incidences disempowering language associated processes...
We have previously reported primary endpoints of a clinical trial testing two vaccine platforms for the delivery Plasmodium vivax malaria DBPRII: viral vectors (ChAd63, MVA), and protein/adjuvant (PvDBPII with 50µg Matrix-M™ adjuvant). Delayed boosting was necessitated due to halts during pandemic provides an opportunity investigate impact dosing regimens. Here, using flow cytometry – including agnostic definition B cell populations clustering tool CITRUS we report enhanced induction...
Abstract There is an ongoing global effort to design, manufacture, and clinically assess vaccines against SARS-CoV-2. Over the course of pandemic a number new SARS-CoV-2 virus isolates or variants concern (VoC) have been identified containing mutations in key proteins. In this study we describe generation preclinical assessment ChAdOx1-vectored vaccine (AZD2816) which expresses spike protein Beta VoC (B.1.351). We demonstrate that AZD2816 immunogenic after single dose. When used as booster...
An extremely preterm neonate developed a progressively worsening right axillary ulcerative lesion at the previous site of temperature probe. Despite treatment with broad-spectrum antibiotic and antifungal therapy, worsened required extensive surgical debridement. Histologic examination debrided tissue demonstrated presence invasive mucormycosis. With prompt intervention proper patient survived. Here we present unique case cutaneous mucormycosis in neonate, along review current literature on...